Safety Study of MELK Inhibitor to Treat Patients With Advanced Breast Cancer and Triple Negative Breast Cancer

NCT02926690 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

70

Enrollment

INDUSTRY

Sponsor class

Conditions

Relapsed/Refractory Locally Advanced or Metastatic Breast Cancer and Triple Negative Breast Cancer

Interventions

DRUG: OTS167PO

Sponsor

OncoTherapy Science, Inc.